Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2

Hepatology Research

Volumn 37, Issue 10, 2007, Pages 793-800

  Hasegawa, Eiko ^a   Kobayashi, Masahiro ^a   Kawamura, Yusuke ^a   Yatsuji, Hiromi ^a   Sezaki, Hitomi ^a   Hosaka, Tetsuya ^a   Akuta, Norio ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Cancer prevention; Cirrhosis; Hepatitis C virus; Hepatocellular carcinoma; Interferon

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CHOLINESTERASE; INTERFERON; PEGINTERFERON; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN;

ADULT; AGED; ANAMNESIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHILL; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; FEMALE; FEVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERSTITIAL PNEUMONIA; INTRAOCULAR HEMORRHAGE; JAPANESE; LEUKOPENIA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PRIORITY JOURNAL; RETINOPATHY; RISK ASSESSMENT; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS CARCINOGENESIS; VIRUS LOAD;

EID: 34548170062     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00140.x     Document Type: Article

References (21)

1. Kobayashi M, Ikeda K, Hosaka T et al. Natural history of compensated cirrhosis in the child-pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 2006; 78: 459-65.
2. Ikeda K, Saitoh S, Suzuki Y et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-8.
3. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-6.
4. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-10.
5. Chayama K, Saitoh S, Arase Y et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991; 13: 1040-3.
6. Yoshioka K, Kakumu S, Hyashi H et al. Anti-hepatitis C antibodies in patients with chronic non-A, non B hepatitis: Relation to disease progression and effect of interferon alpha. Am J Gastroenterol 1991; 86: 1495-9.
7. Tsubota A, Chayama K, Ikeda K et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94.
8. Hagiwara H, Hayashi N, Mita E et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 1993; 104: 877-83.
9. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998; 27: 1394-402.
10. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
11. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. Lancet 1998; 351: 1535-9.
12. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29: 1311-16.
13. Ikeda K, Saitoh S, Koboyashi M et al. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study. J Gastroenterol Hepatol 2001; 16: 406-15.
14. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
15. Valla DC, Chevallier M, Marcellen P et al. Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999; 29: 1870-5.
16. Hashimoto M, Chayama K, Tsubota A et al. Typing six major hepatitis C virus genotypes by polymerase chain reaction using primers derived from nucleotide sequences of the NS5 region. Int Hepatol Commun 1996; 4: 263-7.
17. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol 2001; 34: 593-602.
18. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992; 339: 1543.
19. Akuta N, Suzuki F, Tsubota A et al. Efficacy of interferon monotherapy to 394 consecutive naïve cases infected with hepatitis C virus genotype 2a in Japan. J Hepatol 2002; 37: 831-6.
20. Saitoh S, Ikeda K, Koida I et al. Serial hemodynamic measurements in well-differentiated hepatocellular carcinomas. Hepatology 1995; 21: 1530-4.
21. Ikeda K, Arase Y, Saitoh S et al. Anticarcinogenic impact of interferon on patients with chronic hepatitis C: A large-scale long-term study in a single center. Intervirology 2006; 49: 82-90.